BCX Bioceltix S.A.
Bioceltix S.A. engages in the development of veterinary biologics based on mesenchymal stem cells. The company's products include BCX-CM-J, a stem-cell based medicinal drug for the treatment of osteoarthritis in dogs; BCX-CM-AD, an allogeneic stem cell-based medicinal product for the treatment of atopic dermatitis in dogs; and BCX-EM, an allogeneic stem cell-based medicinal product for the treatment of osteoarthritis in horses. It also develops BCX-CM-Sec, a research project aimed at developing a cell-free biological drug to treat atopic dermatitis in dogs. The company was founded in 2016 and is headquartered in Wroclaw, Poland.…
Industry Peers
BiotechnologyKey Statistics
About Bioceltix (WSE: BCX)
›
Bioceltix (WSE: BCX) is listed on Warsaw Stock Exchange, where its shares trade in PLN. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 49 employees.
The shares were at 63.40 PLN on 20 November 2026, down 34.3% over 52 weeks. Its 52-week range is 57.50 PLN to 99.00 PLN: the price is 36.0% below the high and 10.3% above the low.
Its market capitalisation is 350.74M PLN.
Bioceltix reports return on equity of -20.7% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 56.66M PLN. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. One analyst covers the stock; their mean price target of 119.00 PLN is 87.7% above the current price.